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Introduction
Cluster headache (CH) is one of the most distinctive and
painful primary headache disorders in clinical practice. It
is characterised by a series of sudden attacks of severe
pain, lasting from 30 min to 2 h, localised invariably on
one side and the side affected generally is consistent for
every attack and every cluster period.
Most headache disorders seen in emergency departments
are of a benign aetiology, with migraine being responsible
for 60% of all headache presentations. In contrast, CH
accounts for only 2% [1]. Although CH is uncommon in this
and other settings, an accurate diagnosis is important
because it allows for effective treatment for CH and helps to
avoid unnecessary diagnostic and treatment interventions.
Barriers to accurate diagnosis and appropriate treat-
ment include the brevity of the attacks, which may end
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before evaluation, the rarity of the disorder and conse-
quent lack of physician familiarity with its presentation,
and the lack of specificity of the autonomic features.
Epidemiology
CH is considerably less common than migraine and is pre-
dominantly a disease of men. The gender ratio varies
between 5.0:1 and 6.7:1, however recent reviews suggest
a progressive reduction in the male to female ratio.
Estimations in the literature indicate that lifetime preva-
lence of CH is between 0.1% and 0.4% and the incidence is
between 2.5% and 9.8% cases per 100,000 people each year.
CH usually begins between 20 and 40 years (peak to
20 in episodic), but it may begin at any age [2].
Clinical manifestations
The pain is of terrible intensity and is typically described
as boring, tearing and may be likened to a “hot poker in
the eye” or as if “the eye as being pushed out”. Onset is
typically abrupt or preceded by a brief sensation of pres-
sure or mild discomfort in the soon-to-be painful area. The
pain intensifies rapidly, peaking in 5–10 min and may stay
at maximal intensity for 45–90 min. After the attack the
patient is pain-free but exhausted [3].
A notable feature of CH is its short duration; in fact each
untreated attack typically lasts for 15–180 min (average
30–120 min), with more than 75% of attacks reported last-
ing less than 60 min [4]. The location of pain is strictly uni-
lateral and almost always remains on the same side of the
head between cluster periods. Rarely, the pain may occur on
the opposite side in a subsequent period and even less fre-
quently, attacks may switch to the opposite side within the
same cluster period. The pain is typically in the retro-orbital
and temporal region on the affected side. The pain may radi-
ate into the forehead, temple, cheek and jaw. In contrast to
migraine, patients are restless during the attack.
The attacks commonly occur one to three times daily,
although they may be as variable as one every other day to
up to eight daily. The daily attacks usually last for 1–2
months (the cluster period). The headaches then remit
spontaneously only to recur again in a cluster of daily
headaches months to years later [5, 6].
Some patients experience variable sensations
antecedent to their attacks of CH. Those occurring several
minutes to 1 hour before the attack are referred to as pro-
dromal symptoms. Those occurring several hours or days
before the attacks are called premonitory symptoms. These
symptoms may include sensory phenomena such as paraes-
thesias, burning sensations, sharp pains and stabbing pains;
mood changes such as nervousness; alteration in the sleep
pattern such as snoring, erratic sleep and insomnia [7, 8].
We can define two different states of CH: episodic CH is
characterised by attacks that occur in periods lasting 7 days
to 1 year separated by pain-free periods lasting one month
[9]; chronic CH is present when attacks occur without
remission or with remission lasting less than one month.
Treatment of cluster headache
Because of the rapid onset and short time to peak intensi-
ty of the pain of CH, a fast acting symptomatic therapy is
imperative [10]. The solutions that give the most effec-
tive, rapid and reliable relief for attacks of CH are the fol-
lowing.
Sumatriptan
Although the mechanism of migraine attacks remains
unexplained, it is thought that an important role is played
by serotonin receptors, vasodilatation in certain regions
and opening of arteriovenous communication in the head.
Sumatriptan is an agonist of 5-HT1-like receptors and
exerts a selective vasoconstricting effect on the arteries of
the head, particularly in the rami of the carotid artery.
Subcutaneous sumatriptan is the most effective self-
administered medication for the symptomatic relief of CH
[11]. In a placebo-controlled study, 6 mg of sumatriptan
delivered subcutaneously was significantly more effective
than placebo, with 74% of patients having complete relief by
15 min compared with 26% of patients treated with placebo.
However, sumatriptan is not effective when used before
an expected attack in an attempt to prevent an oncoming
attack, nor is it useful as a prophylactic agent. The overall
efficacy of sumatriptan has been reported to be approxi-
mately 8% less in patients with chronic CH than in patients
with episodic cluster headache. Patients with chronic CH
respond very well but to a somewhat lesser extent and
more slowly than patient with episodic CH.
Zolmitriptan
Zolmitriptan is an effective oral agent for the acute treat-
ment of migraine. Recently, a double-blind controlled trial
compared the efficacy of 5 and 10 mg oral zolmitriptan
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with placebo for the treatment of acute CH attacks [12].
With headache response defined as a two-point reduction
on a five-point pain intensity scale at 30 min, response
rates following placebo, 5 and 10 mg of zolmitriptan,
were 29%, 40% and 47%, respectively. The difference
reached statistical significance for 10 mg zolmitriptan
compared with placebo. In addition, significantly more
patients reported mild or no pain 30 min after treatment
with 5 and 10 mg of zolmitriptan than following placebo.
Zolmitriptan is the first orally administered triptan to
demonstrate efficacy in the treatment of CH and remains
a therapeutic option in patients who cannot tolerate oxy-
gen or subcutaneous sumatriptan or for those in whom an
oral medication is desired.
Oxygen
Oxygen inhalation has been the standard of care for the
symptomatic relief of CH since it was introduced as an
effective therapy by Horton. If delivered at the onset of an
attack via a non-rebreathing facial mask at a flow rate of
7 l/min for 15 min, approximately 70% of patients will
obtain relief within 15 min. In some patients, oxygen is
most effective if taken when the pain is at maximal inten-
sity, whereas in others the attack is delayed for minutes to
hours rather than completely aborted [13, 14].
Hyperbaric oxygen
It has been shown that exposure to hyperbaric oxygen is
able not only to interrupt a cluster headache but also to
prevent the successive attacks occurring for 2 or 3 days
after the treatment [15]. The mechanism for this effect has
not been completely clarified but we can already verify
the effect of exposure to hyperbaric condition on the con-
tent of the immunoreactivity to substance P in the nasal
mucosa of CH patients [16, 17]. One of the first experi-
ments was based on 14 patients suffering from an episod-
ic form of CH [18]. The diagnosis was made following the
criteria of the International Headache Society [9]. Before
admission to the trial, each patient provided a complete
history and underwent a physical examination (ears, nose,
throat and a radiography of the chest and electrocardiog-
raphy). The subjects were placed in a multiplace-pluri-
ambient hyperbaric chamber (Galeazzi, La Spezia, Italy).
While in the hyperbaric chamber the subjects breathed
either 100% oxygen saturation (administered through a
facial mask) or environmental air.
Discussion
We have been working on clinical and experimental find-
ings since 1996, in collaboration with the Anaesthetic and
Reanimation Department of Umberto I, and in this time
we have found several confirmations of our first hypothe-
sis about the implementation of this treatment. Although
CH is considered one of the most distinctive and painful
primary headache disorders in clinical practice, because
of the brevity of each attack the management of CH is
possible in the Emergency Department only in the case of
a previous competent diagnosis or after partial or com-
plete recovery, which may have occurred by the time of
evaluation. In this case, the Emergency Department team
may provide the right prophylaxis to the patient or send
the subject to a headache centre equipped with a hyper-
baric chamber. Today we can certainly affirm the positive
effect of hyperbaric oxygen on episodic CH and triptan
non-responder chronic CH.
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